Arkema's Stock Rises 2.96% Despite a 14% Decline in Q1 EBITDA
The specialty chemicals company's stock soared in early trading on Wednesday, May 6, following the CAC 40, which was up 1.43%. The movement coincides with the release of the first quarter 2026 results. The financial calendar also schedules the general meeting on May 21.
The Stock Challenges the Resistance at €65.45 at Opening
Arkema gained 2.96% to €64.45, up from €62.60 at the previous close. The price approached its identified resistance at €65.45, after having risen nearly 11% over three months. The stock is now trading above the upper Bollinger Band limit set at €63.64, a configuration that indicates an acceleration of the bullish trend in recent sessions. The RSI at 61 remains in the neutral zone, without a marked overheating signal. The 50-day moving average, at €58.34, supports the medium-term dynamics. Today's progress follows the same technical sequence as the resistance breach observed in early April, when the stock had validated a threshold break at €62.10.
Q1 Marked by EBITDA Decline, Guidance Confirmed
The company released its first quarter 2026 accounts this Wednesday. The EBITDA fell by 14% to €283 million, affected by an unfavorable exchange rate effect of approximately €20 million and the weakness of the Advanced Materials division. Despite this decline, management confirmed its target of slight EBITDA growth at constant exchange rates for the entirety of 2026. Among the risks mentioned during the Q1 release is the potential impact of the Middle East crisis on global demand and input costs. The sector context remains marked by Brent crude at around $108 per barrel, which weighs on the cost trajectory in the chemical industry. The next calendar appointment: the general meeting on May 21, followed by the publication of the half-year results on July 30.
